Staphylococcal purpura fulminans: A toxin-mediated disease?

Clinical Infectious Diseases

Volumn 40, Issue 7, 2005, Pages 948-950

  Chambers, Henry F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; IMMUNOGLOBULIN; LEUKOCIDIN; PANTON VALENTINE LEUKOCIDIN; STAPHYLOCOCCUS ENTEROTOXIN; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS ENTEROTOXIN C; SUPERANTIGEN; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG;

BACTEREMIA; CAPNOCYTOPHAGA; FULMINATING PURPURA; HUMAN; INCIDENCE; MENINGOCOCCEMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEISSERIA MENINGITIDIS; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTERIAL TOXINS; ENTEROTOXINS; EXOTOXINS; HUMANS; LEUKOCIDINS; PURPURA, SCHOENLEIN-HENOCH; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS;

EID: 15744397013     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428584     Document Type: Note

References (27)

1. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40:941-7 (in this issue).
2. Smith OP, White B. Infectious purpura fulminans: diagnosis and treatment. Br J Haematol 1999; 104:202-7.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273:117-23.
4. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-84.
5. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9:978-84.
6. Campanelli A, Kaya G, Ozsahin AH, et al. Purpura fulminans in a child as a complication of chickenpox infection. Dermatology 2004; 208:262-4.
7. Canpolat C, Bakir M. A case of purpura fulminans secondary to transient protein C deficiency as a complication of chickenpox infection. Turk J Pediatr 2002; 44:148-51.
8. DeFranzo AJ, Marasco P, Argenta LC. Warfarin-induced necrosis of the skin. Ann Plast Surg 1995; 34:203-8.
9. Har-El G. Streptococcal gangrene and purpura fulminans. Head Neck 1992; 14:513.
10. Hoeffel JC, Hoeffel F. Necrotizing fasciitis and purpura fulminans. Plast Reconstr Surg 2002; 109:2165.
11. Huemer GM, Bonatti H, Dunst KM. Purpura fulminans due to E. coli septicemia. Wien Klin Wochenschr 2004; 116:82.
12. Keri JE, Thomas K, Berman B, Falabella A. Purpura fulminans in a patient with malaria. Eur J Dermatol 2000; 10:617-9.
13. Santamaria JP, Kenney S, Stiles AD. Purpura fulminans associated with Haemophilus influenzae type B infection. N C Med J 1985; 46:516-7.
14. Thisyakorn U, Ningsanond V. Purpura fulminans produced by Aeromonas hydrophila: a case report. Southeast Asian J Trop Med Public Health 1985; 16:532-3.
15. Rintala E, Kauppila M, Seppala OP, et al. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000; 28:2373-8.
16. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941; 68:851-75.
17. Wilkox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998; 91:41-7.
18. von Eiff C, Friedrich AW, Peters G, Becker K. Prevalence of genes encoding for members of the staphylococcal leukotoxin family among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 2004; 49:157-62.
19. Nashev D, Toshkova K, Salasia SI, Hassan AA, Lammler C, Zschock M. Distribution of virulence genes of Staphylococcus aureus isolated from stable nasal carriers. FEMS Microbiol Lett 2004; 233:45-52.
20. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for Staphylococcus aureus enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. J Clin Microbiol 2000; 38:1032-5.
21. Peacock SJ, Moore CE, Justice A, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002; 70:4987-96.
22. Larsen HD, Huda A, Eriksen NH, Jensen NE. Differences between Danish bovine and human Staphylococcus aureus isolates in possession of superantigens. Vet Microbiol 2000; 76:153-62.
23. Novick RP. Mobile genetic elements and bacterial toxinoses: the superantigen-encoding pathogenicity islands of Staphylococcus aureus. Plasmid 2003; 49:93-105.
24. Jarraud S, Mougel C, Thioulouse J, et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 2002; 70:631-41.
25. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
26. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102:177-93.
27. de Chalain T, Cohen SR, Burstein FD. Successful use of leeches in the treatment of purpura fulminans. Ann Plast Surg 1995; 35:300-4.